Status:

COMPLETED

18F-FDG Tomography and Labeled Leukocyte Scintigraphy

Lead Sponsor:

Central Hospital, Nancy, France

Conditions:

Malignant Otitis Externa

Eligibility:

All Genders

18-80 years

Brief Summary

The study will aim to show that there is a superiority of 18F-FDG PET/CT compared to labeled leukocyte scintigraphy in patients with a malignant otitis externa.

Detailed Description

The management of malignant otitis externa (MEO) is a major issue in patients who are often polypathological and fragile. Appropriate antibiotic therapy must be started quickly after the diagnosis is ...

Eligibility Criteria

Inclusion

  • patients with malignant otitis externa who received a 18F-FDG positron emission tomography and a labelled leukocyte scintigraphy

Exclusion

  • patients who refuse to have their imaging data used

Key Trial Info

Start Date :

December 18 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 18 2023

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT05994768

Start Date

December 18 2020

End Date

October 18 2023

Last Update

November 30 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Verger Antoine

Vandœuvre-lès-Nancy, France, 54511